Results 51 to 60 of about 38,526 (184)

2026 Update on the Management of Diffuse Large B‐Cell Lymphoma

American Journal of Hematology, EarlyView.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) is the most common type of NHL in the Western Hemisphere. It comprises a heterogenous group of lymphomas, with different biology and clinical prognoses. R‐CHP remains the backbone of therapy, and frontline therapeutic options in fit patients are pola‐R‐CHP and R‐CHOP, whereas elderly or frail/unfit ...
Elise A. Chong, Emily B. Tomasulo, Stefan K. Barta   +2 more
wiley   +1 more source

Mechanisms of spinal glial activation in chemotherapy‐induced peripheral neuropathy: Focus on microglia and astrocytes

Ibrain, EarlyView.
Chemotherapy‐induced peripheral neuropathy (CIPN) remains a major clinical challenge, with central sensitization considered an important pathological mechanism in its occurrence and persistence. This review focuses on spinal astrocytes and microglia, systematically summarizing the pathological mechanisms of spinal glial cells involved in CIPN caused by
Long Gu, Song Cao, Yonghuai Feng
wiley   +1 more source

Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model

BMC Cancer, 2012
Background Despite recent advances in the treatment of hepatocellular carcinoma (HCC), the chemotherapy efficacy against HCC is still unsatisfactory.
Wang Cun, Gao Dongmei, Guo Kun, Kang Xiaonan, Jiang Kai, Sun Chun, Li Yan, Sun Lu, Shu Hong, Jin Guangzhi, Sun Haiyan, Wu Weizhong, Liu Yinkun   +12 more
doaj   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, EarlyView.
What's New? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells

Haematologica, 2015
Proteasome inhibitor resistance is a challenge for myeloma therapy. Bortezomib targets the β5 and β1 activity, but not the β2 activity of the proteasome.
Marianne Kraus, Juergen Bader, Paul P. Geurink, Emily S. Weyburne, Anne C. Mirabella, Tobias Silzle, Tamer B. Shabaneh, Wouter A. van der Linden, Gerjan de Bruin, Sarah R. Haile, Eva van Rooden, Christina Appenzeller, Nan Li, Alexei F. Kisselev, Herman Overkleeft, Christoph Driessen   +15 more
doaj   +1 more source

Therapeutic Options for IgA Pemphigus in Patients Refractory to Dapsone

JEADV Clinical Practice, EarlyView.
ABSTRACT IgA pemphigus is a rare autoimmune blistering disorder with limited therapeutic guidance available due to its rarity and complex presentation. This comprehensive analysis evaluates the therapeutic outcomes of 67 published patients, emphasising the significant role of dapsone as the first‐line treatment.
Lorenz Frasheri, Marta Dechant, Tilo Biedermann   +2 more
wiley   +1 more source

Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States.

PLoS ONE, 2016
This study is a pharmacoepidemiologic description of pediatric bortezomib use. Exposure was identified through billing codes in patients admitted to US children's hospitals that participated with the Pediatric Health Information System between 2004 and ...
Amanda M DiNofia, Elizabeth Salazar, Alix E Seif, Yimei Li, Yuan-Shung Vera Huang, Rochelle Bagatell, Brian T Fisher, Richard Aplenc   +7 more
doaj   +1 more source

Fat Mass and Obesity‐Associated Protein Contributes to Tumorigenesis and Drug Resistance of Diffuse Large B‐Cell Lymphoma by Suppressing N6‐Methyladenosine Methylation of Myc

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Ibrutinib resistance remains a major obstacle in the treatment of diffuse large B‐cell lymphoma (DLBCL). Fat mass and obesity‐associated protein (FTO) has been implicated in drug resistance through its regulation of N6‐methyladenosine (m6A) modifications; however, whether FTO mediates ibrutinib resistance in DLBCL remains unclear.
Ting‐Ting Lu, Jin‐Hao Chen, Yan‐Fang Wang, Xiao Wu, Hui‐Yun Ni, Qiu‐Rong Zhang   +5 more
wiley   +1 more source

Bortezomib Prescription Pattern for the Treatment of Multiple Myeloma by Hematologists in Nigeria

Journal of Global Oncology, 2017
Purpose: Novel therapy has dramatically changed the outcome of patients with myeloma. Current National Comprehensive Cancer Network guidelines give bortezomib-based combinations a central role in the management of multiple myeloma (MM).
Kaladada I. Korubo, Anazoeze J. Madu, Helen C. Okoye, Benedict Nwogoh   +3 more
doaj   +1 more source

Oncogenic KRAS Rewires Stress Granule Dynamics: Mechanisms and Therapeutic Opportunities

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Stress granules (SGs) are dynamic, membrane‐less structures that form in response to various cellular stresses, including metabolic, oxidative, and therapeutic challenges. They function as adaptive hubs and reorganize protein synthesis and signaling networks to help cells survive under stress. In cancer, these condensates are often hijacked to
Msimisi Ndzinisa, Birhanetensay Masresha Altaye, Yuh‐Pyng Sher   +2 more
wiley   +1 more source